Palvella Therapeutics (NASDAQ: PVLA) director receives grant of 3,000 stock options
Rhea-AI Filing Summary
Palvella Therapeutics director George M. Jenkins received a grant of stock options for 3,000 shares of common stock. The options have an exercise price of $102.19 per share and expire on June 10, 2036. They vest on the earlier of the first anniversary of the grant date or the company’s next annual stockholder meeting, subject to his continued service. After this grant, he holds 3,000 options directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
JENKINS GEORGE M
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 3,000 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 3,000 shares (Direct)
Footnotes (1)
- [object Object]
Key Figures
Options granted: 3,000 options
Exercise price: $102.19 per share
Expiration date: June 10, 2036
+2 more
5 metrics
Options granted
3,000 options
Stock Option (Right to Buy) granted June 10, 2026
Exercise price
$102.19 per share
Conversion or exercise price of stock options
Expiration date
June 10, 2036
Option term for director grant
Underlying shares
3,000 shares
Common stock underlying the option grant
Post-grant holdings
3,000 options
Total derivative securities following this transaction
Key Terms
Stock Option (Right to Buy), exercise price, vesting, annual meeting of stockholders, +1 more
5 terms
Stock Option (Right to Buy) financial
"security_title: Stock Option (Right to Buy)"
exercise price financial
"conversion_or_exercise_price: 102.1900"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
vesting financial
"The shares subject to this option shall vest upon the earlier of (i) the first anniversary of the grant date or (ii) the date of the Issuer's next annual meeting of stockholders"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
annual meeting of stockholders financial
"the date of the Issuer's next annual meeting of stockholders following the grant date"
Grant, award, or other acquisition financial
"transaction_code_description: Grant, award, or other acquisition"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What insider transaction did PVLA director George M. Jenkins report on this Form 4?
George M. Jenkins reported receiving a grant of stock options for 3,000 shares of Palvella Therapeutics common stock. The options were awarded as compensation and are not an open-market purchase or sale of existing shares.
What is the exercise price and expiration date of George Jenkins’ PVLA stock options?
The granted stock options have an exercise price of $102.19 per share and expire on June 10, 2036. This means Jenkins can buy up to 3,000 shares at $102.19 any time before expiration, subject to vesting.
How and when do George Jenkins’ Palvella Therapeutics stock options vest?
The options vest on the earlier of the first anniversary of the June 10, 2026 grant date or the next annual meeting of stockholders. Vesting is conditioned on Jenkins’ continued service through the applicable vesting date, according to the Form 4 footnote.
How many Palvella Therapeutics options does George Jenkins hold after this transaction?
Following this grant, George Jenkins holds 3,000 stock options directly, each for one share of common stock. This Form 4 does not show any additional derivative positions, so the 3,000 options represent his reported derivative holdings in this filing.